The Market Reports

Index

1 Neurodegenerative Drugs Market Overview
1.1 Product Overview and Scope of Neurodegenerative Drugs
1.2 Neurodegenerative Drugs Segment by Type
1.2.1 Global Neurodegenerative Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Neurodegenerative Drugs Segment by Application
1.3.1 Global Neurodegenerative Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Global Neurodegenerative Drugs Market Size Estimates and Forecasts
1.4.1 Global Neurodegenerative Drugs Revenue 2016-2027
1.4.2 Global Neurodegenerative Drugs Sales 2016-2027
1.4.3 Neurodegenerative Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 Neurodegenerative Drugs Market Competition by Manufacturers
2.1 Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Neurodegenerative Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Neurodegenerative Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Neurodegenerative Drugs Manufacturing Sites, Area Served, Product Type
2.5 Neurodegenerative Drugs Market Competitive Situation and Trends
2.5.1 Neurodegenerative Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Neurodegenerative Drugs Players Market Share by Revenue
2.5.3 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Neurodegenerative Drugs Retrospective Market Scenario by Region
3.1 Global Neurodegenerative Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Neurodegenerative Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Neurodegenerative Drugs Market Facts & Figures by Country
3.3.1 North America Neurodegenerative Drugs Sales by Country
3.3.2 North America Neurodegenerative Drugs Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Neurodegenerative Drugs Market Facts & Figures by Country
3.4.1 Europe Neurodegenerative Drugs Sales by Country
3.4.2 Europe Neurodegenerative Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Neurodegenerative Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Neurodegenerative Drugs Sales by Region
3.5.2 Asia Pacific Neurodegenerative Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Neurodegenerative Drugs Market Facts & Figures by Country
3.6.1 Latin America Neurodegenerative Drugs Sales by Country
3.6.2 Latin America Neurodegenerative Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Neurodegenerative Drugs Sales by Country
3.7.2 Middle East and Africa Neurodegenerative Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Neurodegenerative Drugs Historic Market Analysis by Type
4.1 Global Neurodegenerative Drugs Sales Market Share by Type (2016-2021)
4.2 Global Neurodegenerative Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Neurodegenerative Drugs Price by Type (2016-2021)

5 Global Neurodegenerative Drugs Historic Market Analysis by Application
5.1 Global Neurodegenerative Drugs Sales Market Share by Application (2016-2021)
5.2 Global Neurodegenerative Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Neurodegenerative Drugs Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Novartis Neurodegenerative Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Pfizer Neurodegenerative Drugs Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Merck Serono
6.3.1 Merck Serono Corporation Information
6.3.2 Merck Serono Description and Business Overview
6.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Merck Serono Neurodegenerative Drugs Product Portfolio
6.3.5 Merck Serono Recent Developments/Updates
6.4 Biogen Idec
6.4.1 Biogen Idec Corporation Information
6.4.2 Biogen Idec Description and Business Overview
6.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
6.4.5 Biogen Idec Recent Developments/Updates
6.5 TEVA
6.5.1 TEVA Corporation Information
6.5.2 TEVA Description and Business Overview
6.5.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 TEVA Neurodegenerative Drugs Product Portfolio
6.5.5 TEVA Recent Developments/Updates
6.6 UCB
6.6.1 UCB Corporation Information
6.6.2 UCB Description and Business Overview
6.6.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 UCB Neurodegenerative Drugs Product Portfolio
6.6.5 UCB Recent Developments/Updates
6.7 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
6.7.5 Boehringer Ingelheim Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Sanofi Neurodegenerative Drugs Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 GlaxoSmithKline
6.9.1 GlaxoSmithKline Corporation Information
6.9.2 GlaxoSmithKline Description and Business Overview
6.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.9.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
6.9.5 GlaxoSmithKline Recent Developments/Updates
6.10 Livzon Pharmaceutical
6.10.1 Livzon Pharmaceutical Corporation Information
6.10.2 Livzon Pharmaceutical Description and Business Overview
6.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.10.5 Livzon Pharmaceutical Recent Developments/Updates
6.11 Haisco Pharmaceutical
6.11.1 Haisco Pharmaceutical Corporation Information
6.11.2 Haisco Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.11.5 Haisco Pharmaceutical Recent Developments/Updates
6.12 Jingxin Pharmaceutical
6.12.1 Jingxin Pharmaceutical Corporation Information
6.12.2 Jingxin Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.12.5 Jingxin Pharmaceutical Recent Developments/Updates
6.13 Dongcheng Biochemicals
6.13.1 Dongcheng Biochemicals Corporation Information
6.13.2 Dongcheng Biochemicals Neurodegenerative Drugs Description and Business Overview
6.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
6.13.5 Dongcheng Biochemicals Recent Developments/Updates
6.14 Hisun Pharmaceutical
6.14.1 Hisun Pharmaceutical Corporation Information
6.14.2 Hisun Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.14.5 Hisun Pharmaceutical Recent Developments/Updates
6.15 Luye Pharma
6.15.1 Luye Pharma Corporation Information
6.15.2 Luye Pharma Neurodegenerative Drugs Description and Business Overview
6.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
6.15.5 Luye Pharma Recent Developments/Updates
6.16 Ark Pharmaceutical
6.16.1 Ark Pharmaceutical Corporation Information
6.16.2 Ark Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.16.5 Ark Pharmaceutical Recent Developments/Updates
6.17 Kanghong Pharmaceutical
6.17.1 Kanghong Pharmaceutical Corporation Information
6.17.2 Kanghong Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.17.5 Kanghong Pharmaceutical Recent Developments/Updates
6.18 Huahai Pharmaceutical
6.18.1 Huahai Pharmaceutical Corporation Information
6.18.2 Huahai Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.18.5 Huahai Pharmaceutical Recent Developments/Updates
6.19 BORA PHARMACEUTICALS
6.19.1 BORA PHARMACEUTICALS Corporation Information
6.19.2 BORA PHARMACEUTICALS Neurodegenerative Drugs Description and Business Overview
6.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2016-2021)
6.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
6.19.5 BORA PHARMACEUTICALS Recent Developments/Updates

7 Neurodegenerative Drugs Manufacturing Cost Analysis
7.1 Neurodegenerative Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Neurodegenerative Drugs
7.4 Neurodegenerative Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Neurodegenerative Drugs Distributors List
8.3 Neurodegenerative Drugs Customers

9 Neurodegenerative Drugs Market Dynamics
9.1 Neurodegenerative Drugs Industry Trends
9.2 Neurodegenerative Drugs Growth Drivers
9.3 Neurodegenerative Drugs Market Challenges
9.4 Neurodegenerative Drugs Market Restraints

10 Global Market Forecast
10.1 Neurodegenerative Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Neurodegenerative Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Neurodegenerative Drugs by Type (2022-2027)
10.2 Neurodegenerative Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Neurodegenerative Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Neurodegenerative Drugs by Application (2022-2027)
10.3 Neurodegenerative Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Neurodegenerative Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Neurodegenerative Drugs by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Neurodegenerative Drugs Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Neurodegenerative Drugs Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Neurodegenerative Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Neurodegenerative Drugs Covered in This Study
Table 5. Global Neurodegenerative Drugs Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Neurodegenerative Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Neurodegenerative Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Neurodegenerative Drugs Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Neurodegenerative Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Neurodegenerative Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Neurodegenerative Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Neurodegenerative Drugs Sales by Region (2016-2021) & (K Units)
Table 16. Global Neurodegenerative Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Neurodegenerative Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Neurodegenerative Drugs Sales by Country (2016-2021) & (K Units)
Table 19. North America Neurodegenerative Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Neurodegenerative Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Neurodegenerative Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Neurodegenerative Drugs Sales by Country (2016-2021) & (K Units)
Table 23. Europe Neurodegenerative Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Neurodegenerative Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Neurodegenerative Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Neurodegenerative Drugs Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Neurodegenerative Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Neurodegenerative Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Neurodegenerative Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Neurodegenerative Drugs Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Neurodegenerative Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Neurodegenerative Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Neurodegenerative Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Neurodegenerative Drugs Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Neurodegenerative Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Neurodegenerative Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Neurodegenerative Drugs Sales (K Units) by Type (2016-2021)
Table 39. Global Neurodegenerative Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Neurodegenerative Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Neurodegenerative Drugs Revenue Share by Type (2016-2021)
Table 42. Global Neurodegenerative Drugs Price (US$/Unit) by Type (2016-2021)
Table 43. Global Neurodegenerative Drugs Sales (K Units) by Application (2016-2021)
Table 44. Global Neurodegenerative Drugs Sales Market Share by Application (2016-2021)
Table 45. Global Neurodegenerative Drugs Revenue (Million US$) by Application (2016-2021)
Table 46. Global Neurodegenerative Drugs Revenue Share by Application (2016-2021)
Table 47. Global Neurodegenerative Drugs Price (US$/Unit) by Application (2016-2021)
Table 48. Novartis Corporation Information
Table 49. Novartis Description and Business Overview
Table 50. Novartis Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. Novartis Neurodegenerative Drugs Product
Table 52. Novartis Recent Developments/Updates
Table 53. Pfizer Corporation Information
Table 54. Pfizer Description and Business Overview
Table 55. Pfizer Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Pfizer Neurodegenerative Drugs Product
Table 57. Pfizer Recent Developments/Updates
Table 58. Merck Serono Corporation Information
Table 59. Merck Serono Description and Business Overview
Table 60. Merck Serono Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Merck Serono Neurodegenerative Drugs Product
Table 62. Merck Serono Recent Developments/Updates
Table 63. Biogen Idec Corporation Information
Table 64. Biogen Idec Description and Business Overview
Table 65. Biogen Idec Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Biogen Idec Neurodegenerative Drugs Product
Table 67. Biogen Idec Recent Developments/Updates
Table 68. TEVA Corporation Information
Table 69. TEVA Description and Business Overview
Table 70. TEVA Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. TEVA Neurodegenerative Drugs Product
Table 72. TEVA Recent Developments/Updates
Table 73. UCB Corporation Information
Table 74. UCB Description and Business Overview
Table 75. UCB Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. UCB Neurodegenerative Drugs Product
Table 77. UCB Recent Developments/Updates
Table 78. Boehringer Ingelheim Corporation Information
Table 79. Boehringer Ingelheim Description and Business Overview
Table 80. Boehringer Ingelheim Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. Boehringer Ingelheim Neurodegenerative Drugs Product
Table 82. Boehringer Ingelheim Recent Developments/Updates
Table 83. Sanofi Corporation Information
Table 84. Sanofi Description and Business Overview
Table 85. Sanofi Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. Sanofi Neurodegenerative Drugs Product
Table 87. Sanofi Recent Developments/Updates
Table 88. GlaxoSmithKline Corporation Information
Table 89. GlaxoSmithKline Description and Business Overview
Table 90. GlaxoSmithKline Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. GlaxoSmithKline Neurodegenerative Drugs Product
Table 92. GlaxoSmithKline Recent Developments/Updates
Table 93. Livzon Pharmaceutical Corporation Information
Table 94. Livzon Pharmaceutical Description and Business Overview
Table 95. Livzon Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. Livzon Pharmaceutical Neurodegenerative Drugs Product
Table 97. Livzon Pharmaceutical Recent Developments/Updates
Table 98. Haisco Pharmaceutical Corporation Information
Table 99. Haisco Pharmaceutical Description and Business Overview
Table 100. Haisco Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. Haisco Pharmaceutical Neurodegenerative Drugs Product
Table 102. Haisco Pharmaceutical Recent Developments/Updates
Table 103. Jingxin Pharmaceutical Corporation Information
Table 104. Jingxin Pharmaceutical Description and Business Overview
Table 105. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 106. Jingxin Pharmaceutical Neurodegenerative Drugs Product
Table 107. Jingxin Pharmaceutical Recent Developments/Updates
Table 108. Dongcheng Biochemicals Corporation Information
Table 109. Dongcheng Biochemicals Description and Business Overview
Table 110. Dongcheng Biochemicals Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 111. Dongcheng Biochemicals Neurodegenerative Drugs Product
Table 112. Dongcheng Biochemicals Recent Developments/Updates
Table 113. Hisun Pharmaceutical Corporation Information
Table 114. Hisun Pharmaceutical Description and Business Overview
Table 115. Hisun Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 116. Hisun Pharmaceutical Neurodegenerative Drugs Product
Table 117. Hisun Pharmaceutical Recent Developments/Updates
Table 118. Luye Pharma Corporation Information
Table 119. Luye Pharma Description and Business Overview
Table 120. Luye Pharma Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 121. Luye Pharma Neurodegenerative Drugs Product
Table 122. Luye Pharma Recent Developments/Updates
Table 123. Ark Pharmaceutical Corporation Information
Table 124. Ark Pharmaceutical Description and Business Overview
Table 125. Ark Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 126. Ark Pharmaceutical Neurodegenerative Drugs Product
Table 127. Ark Pharmaceutical Recent Developments/Updates
Table 128. Kanghong Pharmaceutical Corporation Information
Table 129. Kanghong Pharmaceutical Description and Business Overview
Table 130. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 131. Kanghong Pharmaceutical Neurodegenerative Drugs Product
Table 132. Kanghong Pharmaceutical Recent Developments/Updates
Table 133. Huahai Pharmaceutical Corporation Information
Table 134. Huahai Pharmaceutical Description and Business Overview
Table 135. Huahai Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 136. Huahai Pharmaceutical Neurodegenerative Drugs Product
Table 137. Huahai Pharmaceutical Recent Developments/Updates
Table 138. BORA PHARMACEUTICALS Corporation Information
Table 139. BORA PHARMACEUTICALS Description and Business Overview
Table 140. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 141. BORA PHARMACEUTICALS Neurodegenerative Drugs Product
Table 142. BORA PHARMACEUTICALS Recent Developments/Updates
Table 143. Production Base and Market Concentration Rate of Raw Material
Table 144. Key Suppliers of Raw Materials
Table 145. Neurodegenerative Drugs Distributors List
Table 146. Neurodegenerative Drugs Customers List
Table 147. Neurodegenerative Drugs Market Trends
Table 148. Neurodegenerative Drugs Growth Drivers
Table 149. Neurodegenerative Drugs Market Challenges
Table 150. Neurodegenerative Drugs Market Restraints
Table 151. Global Neurodegenerative Drugs Sales Forecast by Type (2022-2027) & (K Units)
Table 152. Global Neurodegenerative Drugs Sales Market Share Forecast by Type (2022-2027)
Table 153. Global Neurodegenerative Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 154. Global Neurodegenerative Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 155. Global Neurodegenerative Drugs Sales Forecast by Application (2022-2027) & (K Units)
Table 156. Global Neurodegenerative Drugs Sales Market Share Forecast by Application (2022-2027)
Table 157. Global Neurodegenerative Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 158. Global Neurodegenerative Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 159. Global Neurodegenerative Drugs Sales Forecast by Region (2022-2027) & (K Units)
Table 160. Global Neurodegenerative Drugs Sales Market Share Forecast by Region (2022-2027)
Table 161. Global Neurodegenerative Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 162. Global Neurodegenerative Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Neurodegenerative Drugs
Figure 2. Global Neurodegenerative Drugs Market Share by Type in 2020 & 2027
Figure 3. NMDA Product Picture
Figure 4. SSRIs Product Picture
Figure 5. Dopamine Inhibitors Product Picture
Figure 6. Global Neurodegenerative Drugs Market Share by Application in 2020 & 2027
Figure 7. Parkinson’s Disease
Figure 8. Huntington Disease
Figure 9. Amyotrophic Lateral Sclerosis
Figure 10. Alzheimer’s Disease
Figure 11. Global Neurodegenerative Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Neurodegenerative Drugs Market Size 2016-2027 (US$ Million)
Figure 13. Global Neurodegenerative Drugs Sales 2016-2027 (K Units)
Figure 14. Global Neurodegenerative Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 15. Neurodegenerative Drugs Sales Share by Manufacturers in 2020
Figure 16. Global Neurodegenerative Drugs Revenue Share by Manufacturers in 2020
Figure 17. The Global 5 and 10 Largest Neurodegenerative Drugs Players: Market Share by Revenue in 2020
Figure 18. Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 19. Global Neurodegenerative Drugs Sales Market Share by Region (2016-2021)
Figure 20. Global Neurodegenerative Drugs Sales Market Share by Region in 2020
Figure 21. Global Neurodegenerative Drugs Revenue Market Share by Region (2016-2021)
Figure 22. Global Neurodegenerative Drugs Revenue Market Share by Region in 2020
Figure 23. United States Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Canada Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Germany Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. France Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. U.K. Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Italy Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Russia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. China Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Japan Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. South Korea Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. India Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Australia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. China Taiwan Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Indonesia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Thailand Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Malaysia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Mexico Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Brazil Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Argentina Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Turkey Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Saudi Arabia Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. UAE Neurodegenerative Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Sales Market Share of Neurodegenerative Drugs by Type (2016-2021)
Figure 46. Sales Market Share of Neurodegenerative Drugs by Application (2016-2021)
Figure 47. Sales Market Share of Neurodegenerative Drugs by Application in 2020
Figure 48. Revenue Share of Neurodegenerative Drugs by Application (2016-2021)
Figure 49. Revenue Share of Neurodegenerative Drugs by Application in 2020
Figure 50. Manufacturing Cost Structure of Neurodegenerative Drugs
Figure 51. Manufacturing Process Analysis of Neurodegenerative Drugs
Figure 52. Neurodegenerative Drugs Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed